Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
NovoCure Ltd director Allyson J. Ocean received new equity awards. She was granted 11,610 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant or the day immediately preceding the company’s 2027 annual general meeting of shareholders.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest on the same schedule and expire on June 3, 2036. Following the restricted stock unit grant, she directly holds 22,934 ordinary shares.
NovoCure Ltd director Timothy J. Scannell received new equity awards as part of his compensation. On June 3, 2026, he was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares at an exercise price of $16.15 per share.
The restricted stock units and options are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. After the restricted stock unit grant, Scannell directly holds 25,898 ordinary shares.
NovoCure Ltd director Jeryl L. Hilleman received new equity awards. On June 3, 2026, she was granted 11,610 Ordinary Shares as restricted stock units and 16,999 stock options with a $16.15 exercise price.
The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The stock options follow the same vesting schedule and will become fully exercisable at that time. After the share grant, Hilleman directly holds 25,471 Ordinary Shares, and the option grant represents her reported derivative position in this filing.
NovoCure Ltd director David Hung reported receiving equity awards on ordinary shares. He was granted 11,610 restricted stock units, bringing his direct holdings to 32,075 ordinary shares after the award. He also received options for 16,999 ordinary shares at an exercise price of $16.1500 per share. The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The options are scheduled to fully vest and become exercisable on the same timetable, and will expire on June 3, 2036 if not exercised.
NovoCure Ltd director Martin J. Madden received new equity awards as part of his compensation. He was granted 11,610 ordinary shares in the form of restricted stock units, which are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
He was also granted stock options covering 16,999 ordinary shares at an exercise price of $16.15 per share, expiring in 2036. These options will fully vest and become exercisable on the same schedule as the restricted stock units. Following the share grant, Madden directly holds 30,284 ordinary shares.
NovoCure Ltd director Vernon W. Anthony reported equity compensation awards. He received 11,610 ordinary shares in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual general meeting of shareholders. He also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest and become exercisable on the same schedule and expire on June 3, 2036. Following these awards, he holds 209,267 ordinary shares directly.
NovoCure Ltd director Gabriel Leung reported a mandatory sale of 2,945 Ordinary Shares to cover taxes on vested Restricted Stock Units. The shares were sold on an open-market basis at a weighted average price of $15.7707 per share. According to the company’s equity incentive plan, this “sell to cover” transaction was required to satisfy tax withholding obligations and was not a discretionary trade by Leung. After the sale, he directly holds 89,499 NovoCure Ordinary Shares.
NovoCure Ltd director Kristin Stafford reported a mandated sale of 2,945 Ordinary Shares. The shares were sold on June 2, 2026 at a weighted average price of $15.7707 per share to cover tax withholding obligations tied to vesting Restricted Stock Units.
The company’s equity incentive plan requires these tax payments to be funded through a “sell to cover” transaction, so this was not a discretionary trade. After the sale, Stafford directly holds 11,324 Ordinary Shares. The transaction was executed in multiple trades between $15.65 and $15.88 per share.
NovoCure Ltd director Allyson J. Ocean reported a mandated sale of ordinary shares linked to equity compensation. On June 2, 2026, she sold 2,945 ordinary shares at a weighted average price of $15.7707 per share.
According to the disclosure, the shares were sold solely to cover tax withholding obligations from the vesting of Restricted Stock Units under NovoCure’s equity incentive plans and did not represent a discretionary trade. Following this transaction, she directly holds 11,324 ordinary shares of NovoCure.